Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2009 - 2017)

Vertex Pharmaceuticals has reported Current Deferred Revenue for 9 years, with the latest figure at $5.2 million in Q4 2017.

• For the quarter ending Q4 2017, Current Deferred Revenue fell 13.92% year-over-year to $5.2 million; the trailing twelve-month figure through Dec 2017 stood at $5.2 million (down 13.92% YoY), and the FY2017 full-year result was $5.2 million, down 13.92% from the prior year.
• Current Deferred Revenue for Q4 2017 stood at $5.2 million, down from $13.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $35.5 million in Q1 2013, with the low at $5.2 million in Q4 2017.
• Average Current Deferred Revenue over 5 years is $17.5 million, with a median of $15.4 million recorded in 2015.
• Year-over-year, Current Deferred Revenue slumped 63.15% in 2016 and soared 40.62% in 2017.
• Tracing VRTX's Current Deferred Revenue over 5 years: stood at $21.5 million in 2013, then declined by 18.79% to $17.5 million in 2014, then dropped by 6.71% to $16.3 million in 2015, then tumbled by 63.15% to $6.0 million in 2016, then slipped by 13.92% to $5.2 million in 2017.
• The last three Current Deferred Revenue figures came in at $5.2 million (Q4 2017), $13.0 million (Q3 2017), and $7.3 million (Q2 2017), per Business Quant data.

Peer Comparison